It’s been over two months since I updated my database of Adipose Stem Cell Clinical Trials. I am tracking registered Clinical Trials in the ClinicalTrials.gov database. A lot has happened in only two months! Eight new Clinical Trials have been registered in the ClinicalTrials.gov database since June 1, 2012. This brings the all time total of Adipose Stem Cell Clinical Trials to 62. >> Continue reading Adipose Stem Cell Clinical Trial Update- August 2012 (part 4)
Many patients are afraid of the tummy tuck procedure because they have seen friends’ scars or pictures of scars on the Internet and they think such scars are unavoidable. Still others, including Hispanic, Orientals, or African Americans think they are bound to get thick scars simply based on their racial background. This is just not so. Thick or unsightly scars following abdominoplasty can be easily avoided. >> Continue reading Avoiding Thick Tummy Tuck Scars
Spain…..Soccer World Superstar. But what about Stem Cells?!
If there was a World Cup for Stem Cells, Spain would get that too! While Spain is the world leader of Soccer, they are also the dominant player in a new arena of Stem Cell Research. According to information publicly available at ClinicalTrials.gov, Spain is the leader in Clinical Trials using Adipose Stem Cells. And just like Soccer, compared to other countries, it’s not even close!
Adipose Stem Cell Clinical Trial Leaders
As of early June 2012, Spain has registered at least 18 different Clinical Trial locations using Adipose Stem Cells. Mexico and Korea are next with 11 and 10 trials respectively. And what of the great USA, the hot bed of medical innovation? We have a grand total of 3 trials . We pose the question: Has any U.S. money gone to funding these overseas trials? Have any of these trials been funded by U.S. charitable organizations, institutions, or American Venture Capital? While we are happy to see the sector forward *anywhere*, it is somewhat disappointing that U.S. patients have such a limited access to these promising new therapies. We welcome your thoughts on this. >> Continue reading Adipose Stem Cell Clinical Trials by Country-- Spain dominates (part 3)
Most breast augmentation patients are very focused on breast implant size. While that is important, it is only one of the 8 decisions you need to make before having a breast augmentation procedure. I think that the choice of implant incision location is a very important decision that you should discuss with your plastic surgeon in your pre-operative appointment.
In my own Baltimore practice, I always discuss the choice of incision location with patients before the procedure. The incision location is where the breast implant is inserted. Therefore, it is the location where you will have a small scar. In most cases, the scar is barely noticeable, but in any event you should KNOW where your implants will be inserted. >> Continue reading Breast Augmentation: Where do Breast Implants get Inserted?
This week I will focus on whether each of the 54 existing adipose stem cell trials used autologous or allogeneic stem cells. This analysis therefore includes all adipose clinical trials, regardless of recruitment status. Why is knowing whether a clinical trial used autologous or allogeneic adipose stem cells important? It is important because each category represents a different sector of the health care industry. Thus, it gives a hint as to whether Pharma, Device Makers, or Personalized Medicine are leading the new era of Regenerative Medicine. >> Continue reading Adipose Stem Cell Clinical Trials by Donor Source (part 2)
Anyone who reads this blog knows that we are passionate about the future of adipose stem cells, the stem cells that are derived from your own fat. Many people know about their ability to enhance fat grafts for breast reconstruction, but we hear very little in the general media about their ability to cure and treat many diseases. Unless you are a biotech investor hanging out in Cytori message boards, you may not know that many Phase I clinical trials with adipose stem cells have even been completed. >> Continue reading Adipose Stem Cell Clinical Trial Update June 2012
While Friday the 13th may be bad luck for some, such was not the case for the U.S. stem cell industry. On Friday, April 13, the Texas Medical Board (TMB) approved the first set of regulations which will allow physicians to offer autologous adult stem cell therapies. And on Monday, April 16, the Wall Street Journal posted an Op Ed piece written by the former FDA commissioner in support of stem cell therapy. Read on to learn why these recent news items may just spell good news for the stem cell industry, and regen medicine. >> Continue reading Texas Medical Board and WSJ OpEd: Tipping Point for Stem Cell Industry
It is no secret to biotech investors that stem cell stocks suffered dramatic declines in 2011. To be more specific, they were taken out to the woodshed and beat to smithereens. Robin Young summarized that the market capitalization of all the public stem cell sectors declined by 25% in 2011 compared to the previous year. In 2011, total market cap of the entire publicly traded stem cell sector was only $ 3.4 Billion. Every single publicly traded stem cell stock declined in value, except for one company, Mesoblast (ASX: MBX).
At this year’s Stem Cell Summit in NY, Robin Young attributed the steep sector decline to ‘regulatory pushback’. That is code speak to mean that the FDA reversed some of the previous favorable decisions from the past. In one example, an allograph product fom Allosource was already approved, but now the FDA was reclassifying the product from tissue to drug causing major upheaval in the industry.
One of the biggest concerns patients have with any surgery is the amount of pain they will have to endure afterwards. This is especially true in cases of breast augmentation and other cosmetic surgery procedures since the patient is undergoing elective surgery and wants the best experience possible.
Pain itself can have a negative impact following surgery. In fact, it’s the main cause for readmission to a hospital after cosmetic surgery. When patients are in pain, they tend to breathe in short, shallow gasps which results in poor oxygen delivery tot he tissues that, in turn, affects healing. Besides, when the lungs don’t fully expand, patients are more prone to additional complications such as pneumonia.
Several years ago we became fascinated with the potential of adipose stem cells for both cosmetic and medical purposes. However, we soon discovered that nothing in the written FDA guidelines specifically addressed the use of autologous adipose stem cells. Thus began our journey for an answer. In June 2009, we sent a letter to the FDA asking for a position statement on adipose stem cells. Our request focused specifically on autologous, freshly isolated, adipose stem cells for use in reconstruction. These stem cells are from your own fat, for your own usage, and not culture expanded in a lab.
There have been several comments recently on one of my previous blog posts about tummy tuck swelling. While swelling is a definite concern, it’s only one of the possible complications following abdominoplasty. Other complications can include infection, wound separation, and fluid collections. Be sure to discuss these things with your plastic surgeon prior to your surgery. >> Continue reading Tummy Tuck Complications - Infection, Wound Separation, Seroma, Hematoma
Dr. Rodriguez has performed thousands of Cosmetic and Reconstructive surgeries during his 25+ year career. Specializing in multiple procedure makeovers, he is a member of the ASPS and a highly sought after surgeon in the Baltimore/Washington, DC area with 5 star patient reviews from many top medical review sites.
I absolutely LOVE Dr. Rodriquez and his staff. Everyone is very helpful and considerate. Dr. Rodriquez goes above and beyond to please his patients and provides the best results possible!
- Brazilian Butt Lift patient
Ricardo L RodriguezMD, LLC
1300 Bellona Avenue, Suite CLutherville-Timonium,